发布: 2020年09月20日第10卷第18期 DOI: 10.21769/BioProtoc.3755 浏览次数: 6962
评审: Vivien Jane Coulson-ThomasAnonymous reviewer(s)
相关实验方案
人 iPSC 衍生神经元与少突胶质细胞共培养用于髓鞘形成的小分子筛选分析
Stefanie Elke Chie [...] Maria Consolata Miletta
2025年05月05日 1626 阅读
Abstract
Induced pluripotent stem cell derived cardiovascular progenitor cells (iPSC-CVPCs) provide an unprecedented platform for examining the molecular underpinnings of cardiac development and disease etiology, but also have great potential to play pivotal roles in the future of regenerative medicine and pharmacogenomic studies. Biobanks like iPSCORE ( Stacey et al., 2013; Panopoulos et al., 2017), which contain iPSCs generated from hundreds of genetically and ethnically diverse individuals, are an invaluable resource for conducting these studies. Here, we present an optimized, cost-effective and highly standardized protocol for large-scale derivation of human iPSC-CVPCs using small molecules and purification using metabolic selection. We have successfully applied this protocol to derive iPSC-CVPCs from 154 different iPSCORE iPSC lines obtaining large quantities of highly pure cardiac cells. An important component of our protocol is Cell confluency estimates (ccEstimate), an automated methodology for estimating the time when an iPSC monolayer will reach 80% confluency, which is optimal for initiating iPSC-CVPC derivation, and enables the protocol to be readily used across iPSC lines with different growth rates. Moreover, we showed that cellular heterogeneity across iPSC-CVPCs is due to varying proportions of two distinct cardiac cell types: cardiomyocytes (CMs) and epicardium-derived cells (EPDCs), both of which have been shown to have a critical function in heart regeneration. This protocol eliminates the need of iPSC line-to-line optimization and can be easily adapted and scaled to high-throughput studies or to generate large quantities of cells suitable for regenerative medicine applications.
Keywords: Human induced pluripotent stem (iPSC) (人诱导多能干细胞(iPSC))Background
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide and account for about 30% of all mortality causes globally. Coronary artery disease (CAD) and myocardial infarction (MI) are among the most common CVDs, and in the USA alone, every 40 s someone suffers a heart attack (Association, 2016; Heron, 2017; WHO, 2018; Benjamin et al., 2019; D'Antonio-Chronowska et al., 2019a). Heart failure results in the death of cardiac muscle cells and is the consequence of morphological and functional changes (cardiac remodeling: necrosis, scar formation, inflammation, fibrosis, dilation and reshaping) that occur in response to pre-existing cardiac conditions, including CAD, MI, hypertension, cardiomyopathy, myocarditis and abnormal cardiac valve function (Cohn et al., 2000; Reed et al., 2017). Heart failure is commonly treated with beta blockers, ACE inhibitors and aldosterone antagonists which partially reverse cardiac remodeling and thereby improve prognosis (Reis Filho et al., 2015), but does not result in the regeneration of cardiac tissue. There are currently several ongoing clinical trials, including ESCORT and DREAM-HF (Menasche et al., 2015 and 2018; Borow et al., 2019), which are aimed at evaluating the effectiveness of transplanting iPSC-derived Cardiovascular Progenitor Cells (iPSC-CVPCs) or embryonic stem cell derived CVPCs (ESC-CVPCs) as a therapeutic treatment for heart failure. The ability to generate iPSC-CVPCs in large quantities, as is required for regenerative medicine, using biological material obtained directly from the patient would enable autologous transplantations and thereby eliminate the need of immunosuppression. Thus, the development of a robust and cost-effective protocol for generating large amounts of high-quality iPSC-CVPCs without requiring individualized optimization for each iPSC line is imperative for the advancement of future therapeutic treatments of heart failure.
Large collections of iPSC-CVPCs (D'Antonio-Chronowska et al., 2019b) generated from genetically and ethnically diverse individuals could also be used for cost-effective large-scale testing of drugs for cardiotoxicity or proarrhythmic effects. Previous studies (Burridge et al., 2016) and initiatives like CiPA Project (Blinova et al., 2017) have shown the utility of iPSC-CVPCs for testing drugs for cardiotoxicity, which, if scaled to examine large collections of iPSC-CVPCs derived from both healthy or disease bearing individuals, could greatly improve the efficiency of testing new drugs for safety, and in turn decrease the cost of drug development.
We have previously demonstrated the feasibility of using a highly standardized protocol for successfully deriving high quality iPSC-CVPCs from hundreds of iPSC lines reprogrammed from ethnically diverse individuals (D'Antonio-Chronowska et al., 2019b). In this study, we performed 193 differentiations to derive iPSC-CVPCs from 154 iPSCORE iPSC lines (Panopoulos et al., 2017) from 144 individuals. We obtained large numbers of high quality cells, specifically, on average we derived 1.5 x 108 (and up to 6 x 108) cells from a 450 cm2 culture with median cardiac troponin T (cTnT; TNNT2) positive cells of 89.2%. Importantly, while previous differentiation studies acknowledged cellular heterogeneity and the presence of beating cardiomyocytes and non-contractile cell types, the origin and cellular identity of the non-contractile cells had not been addressed. We characterized the 154 iPSC-CVPCs lines using single cell RNA-seq and bulk RNAs-seq and determined that across all the iPSC-CVPC samples there were two distinct fetal-like cardiac cell types: cardiomyocytes (CMs) and epicardium-derived cells (EPDCs), which were present in varying proportions. Of note, both CMs and EPDCs have been show to contribute to the post-infarction heart regeneration (Bargehr et al., 2019). Moreover, our previous studies have shown how molecular characterization of iPSC-CVPCs can result in the identification of genetic variants that contribute to heart development and cardiac pathologies (Benaglio et al., 2019).
Protocols to derive cardiac cells from ESCs or iPSCs have been developed to mimic the processes naturally occurring during cardiogenesis. Initially, cardiac cells were derived as embryoid bodies cultures, first as spontaneous differentiations by culturing ESCs in medium containing 20% fetal calf serum or by stimulation with several reagents known to enhance cardiac differentiation like dimethyl sulfoxide, retinoic acid, or 5-aza-2’-deoxycytidine, after which beating cardiac cells were manually or mechanically purified (Maltsev et al., 1993; Burridge et al., 2014). Differentiation efficiency was greatly improved by the development of directed differentiation protocols that incorporated recombinant proteins including fibroblast growth factor 2, transforming growth factor β, superfamily growth factors activin A and BMP4, vascular endothelial growth factor and the WNT inhibitor DKK-1 proteins (Schneider and Mercola, 2001; Marvin et al., 2001; Beqqali et al., 2006; Laflamme et al., 2007), and by modification of the format of cell differentiation from embryoid bodies to monolayer culture (Paige et al., 2010; Lian et al., 2012). Further advancements were made by the introduction of small molecule protocols (Lian et al., 2012 and 2013) and chemically defined differentiation media (Burridge et al., 2014). Finally, by taking advantage of the adaptation of the developing heart to metabolize lactate, we and others were able to eliminate all non-cardiac cells (Burridge et al., 2014; D'Antonio-Chronowska et al., 2019b; Tohyama et al., 2013). Importantly, previous studies have optimized differentiation protocols to derive cardiac cells from a limited number of iPSC or ESC lines, and in most cases utilized small format culture vessels. Here, we present an optimized, cost-effective and highly standardized protocol which we applied to derive iPSC-CVPCs from 154 genetically and ethnically diverse human iPSC lines in large-sized culture flasks. We optimized the concentration of IWP-2 used to drive the cardiac cell differentiation, which resulted in improved formation of a thick cardiac syncytium and strong wave-like beating (Video 1) (D'Antonio-Chronowska et al., 2019b). We also demonstrated that simple mechanical disruption of the cardiac syncytium prior to metabolic purification of iPSC-CVPCs using lactate results in improved selection and virtually pure cardiac cells (CMs and EPDCs). Additionally, we developed Cell confluency estimates (ccEstimate), an automated method for estimation of cell confluency during the monolayer stage. ccEstimate estimates the point in time for each iPSC line when the monolayer will reach 80% of confluency, which is optimal condition at which to initiate iPSC-CVPC differentiation. Thereby ccEstimate overcomes some of the technical issues in standardizing a differentiation protocol across iPSC lines which have widely varying growth rates. The derived iPSC-CVPCs beat synchronously, are positive for multiple cardiac markers and can be used directly for molecular or electrophysiological assays like multielectrode array (MEA), or they can be cryopreserved for future analysis. Our optimized protocol allowed us to derive high quality iPSC-CVPC samples from 154 iPSC lines generated from ethnically diverse individuals under identical culturing conditions without the requirement of any individualized optimization steps.
Materials and Reagents
Equipment
Software
Procedure
文章信息
版权信息
© 2020 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
D’Antonio-Chronowska, A., D’Antonio, M. and Frazer, K. A. (2020). In vitro Differentiation of Human iPSC-derived Cardiovascular Progenitor Cells (iPSC-CVPCs). Bio-protocol 10(18): e3755. DOI: 10.21769/BioProtoc.3755.
分类
干细胞 > 成体干细胞 > 内皮干细胞/祖细胞
干细胞 > 多能干细胞 > 细胞分化
细胞生物学 > 细胞工程 > 组织工程
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link